Protecting Patient Access to Cancer and Complex Therapies Act
Rep. Murphy Introduces the Protecting Patient Access to Cancer and Complex Therapies Act
This bill is currently in the early stages of the legislative process and is being reviewed by two House committees. It is actively moving forward as it waits for these committees to consider the proposal. There are no upcoming votes scheduled at this time.
Legislative Progress
This bill tries to fix a specific problem for doctors, but it changes a major part of current drug laws that are very controversial in Congress.
Key Points
Impact Analysis
Personal Impact
Life & Work
Independent oncology practices and small medical clinics that administer Part B drugs would continue receiving the full ASP+6% reimbursement rate. Without this bill, the lower negotiated payment rate could squeeze margins for small practices that purchase drugs upfront and depend on the 6% add-on to cover overhead costs like storage, staffing, and administration.
Programs
Disabilities
Milestones
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articlesFor Community Oncology, Good News in Physician Fee Schedule Offset by Potential Wreckage of MFP Proposal
The article discusses the reintroduction of the Protecting Patient Access to Cancer and Complex Therapies Act on July 9, 2025. It explains that the bill aims to decouple physician payment from the Maximum Fair Price (MFP) established by the Inflation Reduction Act, which oncologists warn could cause a 'financial disaster' for practices by slashing reimbursements for high-cost cancer drugs.
Cardinal Health and Bipartisan Lawmakers Signal Support for PACTA to Ensure Fair Reimbursement
Reporting on recent developments in April 2026, this article notes that H.R. 4299 is gaining significant bipartisan support. Industry leaders like Cardinal Health are backing the measure to ensure that community oncology practices remain viable by shifting the financial burden of drug price negotiations from providers to manufacturers via a rebate system.
The Same-Drug Convergence Problem: Interaction Between IRA Negotiation and Federal Drug Discount Programs
This policy analysis explores how H.R. 4299 offers a correction to the Inflation Reduction Act's pricing mechanisms. It details the 'rebate rather than cut' model, where manufacturers pay the government's savings as a direct rebate, preserving the community care infrastructure and preventing the closure of rural chemotherapy centers.
Source Information
Document Type
Congressional Bill
Official Title
Protecting Patient Access to Cancer and Complex Therapies Act
Data Sources
Sponsor
Cosponsors
(30)Analysis generated by AI. Always verify with official sources.